Medicinal composition for treating diabetes and obesity

technical field [0001] The invention belongs to the technical field of medicines, in particular to a pharmaceutical composition for treating diabetes and obesity, the active ingredients of which are sitagliptin and simvastatin / lovastatin. Background technique [0002] Sitagliptin, alias (3R)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[ 4,3-a]pyrazin-7-yl]-4-(2,-trifluorophenyl)butan-1-one, clinically used for type 2 diabetes. This drug is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which controls blood sugar levels by protecting endogenous incretins and enhancing their effects. Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1), are incretins released in response to dietary intake. GLP-1 and GIP can increase insulin synthesis and release from pancreatic β cells through intracellular signaling pathways. GLP-1 can also reduce the secretion of glucagon from pancreatic α cells and reduce hepatic glucose production. However,...